Lead Sponsor

Seagen Inc.

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Have a histologic diagnosis of DLBCL, including transformed histology and follicular grade 3 disease.
•Must have at least one site of biopsy-proven disease demonstrating both of the following: bidimensional measurable disease with the longest axis \>= 1.5cm by radiographic imaging or positive FDG-PET scan at baseline.
•Patients with DLBCL and who have either relapsed, refractory, or progressive disease following salvage therapy, OR relapsed, refractory, or progressive disease following initial therapy and be medically unfit to receive aggressive therapy.
•Either fresh or archived tumor specimen must be available.

•Documented history within 6 months of registration of a cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms.
•Patients who have received allogeneic stem cell transplant.
•Patients with evidence of another invasive primary malignancy within the past three years other than non-melanoma skin cancer, cervical carcinoma in situ, in situ carcinoma of the breast, or fully resected prostate cancer with normal PSA within 8 weeks of registration.
•Patients with any active systemic viral, bacterial, or fungal infection requiring intravenous anti-infectives within 4 weeks prior to first dose of study drug.
•Patients with a history or clinical evidence of leptomeningeal or central nervous system (CNS) lymphoma.

Related studies

NCT06510361 · Lymphoma, Follicular Lymphoma, and more

NCT05442515 · B-NHL, B-Non Hodgkin Lymphoma, and more

NCT07162181 · Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, and more

NCT06528301 · Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), and more

NCT05824585 · Lymphoma, Non-Hodgkin

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL